Skip to main content
Log in

Theophylline Target Concentration in Severe Airways Obstruction — 10 or 20 mg/L?

A Randomised Concentration-Controlled Trial

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

The optimal serum concentration of theophylline for the management of acute airways obstruction was evaluated by comparing the response to target concentrations at the extremes of the usual therapeutic range. 174 patients requiring intravenous theophylline were randomly assigned to a target concentration of 10 or 20 mg/L. Control of theophylline dosage using measured theophylline concentrations and evaluation of efficacy and toxicity was performed under double-blind conditions. 87 patients (50%) required hospital admission. Of these, 54 patients (62%) were followed throughout their hospital admission and reviewed at an outpatient clinic approximately 1 week after discharge. The duration of hospital stay, and rate and extent of improvement in peak expiratory flow rate were not different between the groups. There was significantly more toxicity in the 20 mg/L group. The initial target concentration for theophylline in the management of acute airway obstruction should be 10 mg/L under circumstances where concentration is used to control theophylline dosages.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Chiou WL, Gadalla MAF, Peng GW. Method for the rapid estimation of the total body clearance and adjustment of dosage regimens in patients during a constant rate intravenous infusion. Journal of Pharmacokinetics and Biopharmaceutics 6: 135–151, 1978

    PubMed  CAS  Google Scholar 

  • Cohen J. Statistical power analysis for the behavioural sciences, 2nd ed., pp. 19–74, Lawrence Erlbaum Associates, Hillsdale, NJ, 1988

    Google Scholar 

  • Coleridge J, Cameron P, Epstein J, Tiechtahl H. Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators. Australian and New Zealand Journal of Medicine 23: 348–355, 1993

    Article  PubMed  CAS  Google Scholar 

  • Fairshter RD, Busse WW. Theophylline — how much is enough? Journal of Allergy and Clinical Immunology 77: 646–648, 1986

    Article  PubMed  CAS  Google Scholar 

  • Holford NHG, Hashimoto Y, Sheiner LB. Time and theophylline concentration help explain the recovery of peak flow following acute airways obstruction: population analysis of a randomised concentration controlled trial. Clinical Pharmacokinetics 25: 506–515, 1993

    Article  PubMed  CAS  Google Scholar 

  • Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clinical Pharmacokinetics 6: 429–453, 1981

    Article  PubMed  CAS  Google Scholar 

  • Levine JH, Michael JR, Guarnieri T. Multifocal atrial tachycardia: a toxic effect of theophylline. Lancet 1: 12–14, 1985

    Article  PubMed  CAS  Google Scholar 

  • Littenberg B, Gluck EH. A controlled trial of methylprednisolone in the emergency treatment of acute asthma. New England Journal of Medicine 314: 150–152, 1986

    Article  PubMed  CAS  Google Scholar 

  • Mitenko PA, Ogilvie RI. Rational intravenous doses of theophylline. New England Journal of Medicine 289: 600–603, 1973

    Article  PubMed  CAS  Google Scholar 

  • Murciano D, Auclair MH, Pariente R, Aubier M. A randomized controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. New England Journal of Medicine 320: 1521–1525, 1989

    Article  PubMed  CAS  Google Scholar 

  • Powell JR, Vozeh S, Hopewell P, Costello J, Sheiner LB, et al. Theophylline disposition in acutely hospitalized patients: the effect of smoking, heart failure, severe airways obstruction, and pneumonia. American Review of Respiratory Disease 118: 229–238, 1978

    PubMed  CAS  Google Scholar 

  • Rice KL, Leatherman JW, Duane PG, Snyder LS, Harmon KR, et al. Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine 107: 305–309, 1987

    PubMed  CAS  Google Scholar 

  • Sanathanan LP, Peck CC. The randomized concentration-controlled clinical trial: An evaluation of its sample size efficiency. Controlled Clinical Trials 12: 780–794, 1991

    Article  PubMed  CAS  Google Scholar 

  • Siegel D, Sheppard D, Gelb A, Weinberg PF. Aminophylline increases the toxicity but not the efficacy of an inhaled beta-adrenergic agonist in the treatment of acute exacerbations of asthma. American Review of Respiratory Disease 132: 283–286, 1985

    PubMed  CAS  Google Scholar 

  • Tinkelman DG, Moss BA, Bukantz SC, Sheffer AL, Dobken JH, et al. A multicenter trial of the prophylactic effect of ketotifen, theophylline, and placebo in atopic asthma. Journal Allergy and Clinical Immunology 76: 487–497, 1985

    Article  CAS  Google Scholar 

  • Vozeh S, Kewitz G, Perruchoud A, Tschan M, Kopp C, et al. Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: the optimal use of intravenously administered theophylline. American Review of Respiratory Disease 125: 181–184, 1982

    PubMed  CAS  Google Scholar 

  • Wrenn K, Slovis CM, Murphy F, Greenberg RS. Aminophylline therapy for acute bronchospastic disease in the emergency room. Annals of Internal Medicine 115: 241–247, 1991

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holford, N., Black, P., Couch, R. et al. Theophylline Target Concentration in Severe Airways Obstruction — 10 or 20 mg/L?. Clin. Pharmacokinet. 25, 495–505 (1993). https://doi.org/10.2165/00003088-199325060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199325060-00007

Keywords

Navigation